Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T21:58:23.800Z.
Calculation as of: 2026-10-06T21:58:23.800Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 7871b69def0d47a4b8e1e85f1ab3a71b19ef0e5405565481473c56f3e01c6ed1
PE RATIO
N/A
PE RATIO AVG TTM
N/A
PE RATIO AVG 3Y
N/A
PE RATIO AVG 5Y
N/A
PE RATIO AVG 10Y
N/A
PE RATIO AVG 15Y
N/A
PE RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Market Cap
$3.63M
PE Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$3.53M
PE Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| 60 Degrees Pharmaceuticals, Inc. (SXTP) | $3.90M | N/A | N/A | N/A | N/A |
| Aptevo Therapeutics Inc. (APVO)vs › | $3.93M | N/A | 1.58 | 1.58 | 1.58 |
| GRI Bio, Inc. (GRI)vs › | $4.15M | N/A | N/A | N/A | N/A |
| Evogene Ltd. (EVGN)vs › | $3.65M | N/A | N/A | N/A | N/A |
| Ernexa Therapeutics Inc. (ERNA)vs › | $3.65M | N/A | N/A | N/A | N/A |
| WORK Medical Technology Group Ltd. Class A (WOK)vs › | $3.63M | N/A | N/A | N/A | N/A |
| Processa Pharmaceuticals, Inc. (PCSA)vs › | $4.21M | N/A | N/A | N/A | N/A |
| Cadrenal Therapeutics, Inc. Common Stock (CVKD)vs › | $3.53M | N/A | N/A | N/A | N/A |
| Moolec Science S.A. (MLEC)vs › | $3.50M | N/A | N/A | N/A | N/A |
| Eocene Ltd. (EOCN)vs › | $3.50M | N/A | N/A | N/A | N/A |
Trailing P/E
N/A
Forward P/E
N/A
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$1.11
Forward EPS (Est.)
$-3.16
Forward P/E
N/A
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | PE RATIO |
|---|---|
| 2024-08-14 | 4.08 |
| 2024-08-13 | 4.14 |
| 2024-08-12 | 4.97 |
| 2024-08-09 | 3.44 |
| 2024-08-08 | 3.40 |
| 2024-08-07 | 3.45 |
| 2024-08-06 | 3.81 |
| 2024-08-05 | 4.57 |
| 2024-08-02 | 5.00 |
| 2024-08-01 | 5.06 |
| 2024-07-31 | 5.43 |
| 2024-07-30 | 6.07 |
| 2024-07-29 | 6.72 |
| 2024-07-26 | 6.93 |
| 2024-07-25 | 6.92 |
| 2024-07-24 | 6.50 |
| 2024-07-23 | 6.79 |
| 2024-07-22 | 7.80 |
| 2024-07-19 | 9.98 |
| 2024-07-18 | 9.06 |
| 2024-07-17 | 8.61 |
| 2024-07-16 | 8.61 |
| 2024-07-15 | 8.45 |
| 2024-07-12 | 9.04 |
| 2024-07-11 | 9.06 |
| 2024-07-10 | 8.36 |
| 2024-07-09 | 8.97 |
| 2024-07-08 | 8.51 |
| 2024-07-05 | 8.61 |
| 2024-07-03 | 8.53 |
| 2024-07-02 | 8.84 |
| 2024-07-01 | 9.50 |
| 2024-06-28 | 9.31 |
| 2024-06-27 | 9.89 |
| 2024-06-26 | 9.82 |
| 2024-06-25 | 9.75 |
| 2024-06-24 | 10.32 |
| 2024-06-21 | 10.38 |
| 2024-06-20 | 10.12 |
| 2024-06-18 | 9.85 |
| 2024-06-17 | 10.19 |
| 2024-06-14 | 10.06 |
| 2024-06-13 | 10.37 |
| 2024-06-12 | 11.12 |
| 2024-06-11 | 12.36 |
| 2024-06-10 | 12.85 |
| 2024-06-07 | 12.92 |
| 2024-06-06 | 12.70 |
| 2024-06-05 | 10.52 |
| 2024-06-04 | 10.95 |
| 2024-06-03 | 10.86 |
| 2024-05-31 | 10.75 |
| 2024-05-30 | 10.67 |
| 2024-05-29 | 10.12 |
| 2024-05-28 | 10.04 |
| 2024-05-24 | 11.59 |
| 2024-05-23 | 10.52 |
| 2024-05-22 | 10.57 |
| 2024-05-21 | 10.28 |
| 2024-05-20 | 10.27 |
| 2024-05-17 | 8.28 |
| 2024-05-16 | 8.21 |
